methyldopa
douglas pharmaceuticals limited - methyldopa sesquihydrate 500mg (as the sesquihydrate. 571mg including overage.) - film coated tablet - 500 mg - active: methyldopa sesquihydrate 500mg (as the sesquihydrate. 571mg including overage.) excipient: carmellose magnesium stearate microcrystalline cellulose opaspray povidone starch
methyldopa tablet
mylan institutional inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 500 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.
methyldopa viatris
viatris limited - methyldopa sesquihydrate 283mg equivalent to to 250 mg methyldopa anhydrous; - tablet - 250 mg - active: methyldopa sesquihydrate 283mg equivalent to to 250 mg methyldopa anhydrous excipient: citric acid colloidal silicon dioxide disodium edetate dihydrate ethylcellulose guar gum magnesium stearate opadry yellow oy-8462 purified water sodium starch glycolate - hypertension (mild, moderate or severe).
methyldopa tablet, film coated
accord healthcare inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 125 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.
methyldopa tablet
mylan pharmaceuticals inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients:
methyldopa tablet, film coated
rebel distributors corp - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.
methyldopa tablet, film coated
physicians total care, inc. - methyldopa (unii: 56lh93261y) (methyldopa - unii:56lh93261y) - methyldopa 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.
methyldopa mylan methyldopa (as sesquihydrate) 250 mg tablet bottle
alphapharm pty ltd - methyldopa sesquihydrate -
aldomet
merck sharp & dohme (new zealand) limited - methyldopa sesquihydrate 500mg; - tablet - 500 mg - active: methyldopa sesquihydrate 500mg excipient: carnauba wax citric acid monohydrate colloidal silicon dioxide ethylcellulose guar gum hypromellose iron oxide red magnesium stearate powdered cellulose propylene glycol purified talc quinoline yellow sodium calcium edetate titanium dioxide
prodopa
viatris limited - methyldopa sesquihydrate 566mg equivalent to to 500 mg methyldopa anhydrous - tablet - 500 mg - active: methyldopa sesquihydrate 566mg equivalent to to 500 mg methyldopa anhydrous excipient: citric acid colloidal silicon dioxide disodium edetate dihydrate ethylcellulose guar gum magnesium stearate opadry yellow oy-8462 purified water sodium starch glycolate - hypertension (mild, moderate or severe).